【缺藥訊息】 公告日期：2024/3/19。 缺藥品項：Novomix 胰島素筆 30/70。 缺藥原因：因進口問題缺藥。 替代藥品：院內有同類品。 配套措施：藥品用罄關檔停用，建請改以院內胰島素筆替代。 【藥品性質提示】 ★LASA藥品：NOV02 NovoRapid 3mL/FlexPen (形似) 點擊看LASA藥品外觀比較圖 #高警訊藥品 【藥品訊息】 30/70 NovoMix 胰島素筆 藍 衛教單張

糖尿病 (其他胰島素) Type 1 diabetes mellitus, Type 2 diabetes mellitus
#仿單變更2021

Regulates glucose metabolism by increasing peripheral uptake of glucose and inhibiting glucose production in the liver .

1. Hypersensitivity to insulin aspart, insulin aspart protamine, or to any component of the product
2. Use during hypoglycemia episodes

C(FDA) B3(AUS)

Infant risk cannot be ruled out

Common
Hypoglycemia, abdominal pain, diarrhea, indigestion, backache, musculoskeletal pain, headache , neuropathy, pharyngitis, rhinitis, upper respiratory infection , influenza-like symptoms
Serious
Hypoglycemia (Severe), hypokalemia, hypersensitivity reaction

Dosage:
Administer subQ within 15 minutes before meals twice daily; dose regimens will vary among patients
Combination use with GLP-1 agonist:
1. HbA1c<8%: Novomix 30 dose reduction by 20% (to prevent hypoglycemia)
2. HbA1c>8%: consider dose reduction of Novomix 30 <20210908>

The safety and effectiveness have not been established in pediatric patients

There are no dosage adjustment provided in the manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism

There are no dosage adjustment provided in the manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism

Store unused syringes in refrigerator, between 2 and 8 degrees C. Protect from freezing.